UroMed Reliance European roll-out to begin in Germany later this month.
This article was originally published in The Gray Sheet
Executive SummaryUROMED/ASTRA RELIANCE INSERT MARKETING AGREEMENT commits Astra Tech to invest a minimum of $16 mil. toward the female urinary incontinence device's introduction and marketing in six European countries over a five-year period, UroMed announced Sept. 6. The total investment by Astra Tech, a unit of Swedish pharmaceutical manufacturer Astra AB, could approach $31 mil. over the life of the deal.
You may also be interested in...
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.